NewDirectContract MCPSet up MCP →
Strategy

Direct Contracting for High-Cost Specialty Care: What Self-Insured Employers Need to Know About Oncology, Orthopedics, and Cardiac

Primary care direct contracts are table stakes. The real savings are in specialty care — but oncology, orthopedics, cardiac, and infusion require a fundamentally different negotiating approach and contract structure.

May 25, 2026•8 min read

Direct Contracting for High-Cost Specialty Care: What Self-Insured Employers Need to Know About Oncology, Orthopedics, and Cardiac

Primary care direct contracts are well-established at this point. Employers pay a per-member-per-month fee, employees get same-day access, and utilization of expensive downstream care drops. The model is proven.

Specialty care is a different problem entirely.

Oncology, orthopedics, and cardiac procedures represent a large share of medical spend for many self-insured employers. They are also categories where unit cost variation, site-of-care differences, and avoidable downstream utilization can be extreme.

That spread is not random. It is a negotiating and care-pathway artifact. Direct contracting is one mechanism employers can use to address it.

September 2026 update: specialty contracting is moving upstream

A newer model is emerging alongside traditional bundles and centers of excellence: identify the future specialty claim before the existing referral pathway hardens, then navigate the member into a contracted channel.

World Class Health announced an AI Specialty Clinic on September 2 that it says can identify members likely to need specialty care 60 to 90 days before a claim is filed. One day later, the company launched an infusion offering covering more than 270 specialty infusions, which it says represent 95% of commercial specialty-infusion spend, with average savings of roughly 46% versus commercial hospital outpatient benchmarks for appropriate cases.

The significance is broader than one vendor. Specialty direct contracting is beginning to combine four capabilities that historically sat in separate products: predictive identification, clinical validation, member navigation, and pre-negotiated care.

We break that model down in Why Infusion Is Becoming the Next Battleground for Self-Insured Employer Direct Contracting.


Why Specialty Direct Contracts Are Structurally Different

In a primary care direct contract, you are essentially buying access and time. The financial model is subscription-based. Volume risk is manageable because primary care visits are frequent, predictable, and relatively low-cost per episode.

Specialty care inverts almost every one of those dynamics:

  • Low frequency, high cost per episode. A cardiac bypass can cost tens of thousands of dollars. An employee needs one, not twelve per year.
  • Significant care variation. Two orthopedic surgeons in the same building can produce meaningfully different outcomes, complication rates, and total episode costs.
  • Facility and drug costs can drive the bill. In oncology and infusion, specialty-drug and facility economics may dwarf the professional fee. In orthopedics, implants and facility charges materially affect total episode cost.
  • Bundled or episode-based pricing is common. You are not paying a monthly retainer. You are often pricing a defined clinical event from start to finish.
  • Timing matters. The earlier the employer or care-navigation partner can identify the upcoming episode, the easier it is to influence site of care and provider selection.

The Three Specialty Categories: What Each Deal Looks Like

Oncology

Oncology is the hardest category to structure because care pathways are highly individual. A localized breast cancer case is a fundamentally different financial event than a metastatic cancer case requiring multiple lines of therapy.

A practical direct contracting approach for oncology can include pathway adherence combined with transparent economics on drugs, infusion, and facility services.

Key design elements include:

  • Partnering with a center of excellence or oncology group using evidence-based treatment pathways.
  • Negotiating drug and infusion economics separately where appropriate, rather than relying only on opaque percentage-of-charge arrangements.
  • Building quality metrics into the contract, such as pathway adherence, readmissions, and emergency department utilization during active treatment.
  • Defining how second opinions, genomic testing, specialty pharmacy, and site-of-care decisions are handled.

Orthopedics

Orthopedics is where bundled payments have the longest track record.

The standard structure:

  • Define the bundle. A hip replacement bundle might cover surgery, anesthesia, implant costs, facility services, post-acute care, and a defined complication window.
  • Negotiate implant costs separately. Requiring invoice-based or otherwise transparent implant pricing can remove one major source of variation.
  • Include the post-acute care pathway. Physical therapy, home recovery, and skilled nursing utilization can materially change total episode cost.
  • Set a warranty provision. Some direct contracts include a complication warranty under which the provider absorbs some or all costs related to defined procedure-related readmissions.

Employers without enough procedure volume to negotiate directly may need a purchasing coalition, center-of-excellence vendor, or TPA with existing bundled-payment infrastructure.

Cardiac

Cardiac direct contracting sits between oncology and orthopedics in complexity. Elective procedures can often be bundled. Acute emergencies generally cannot.

Focus direct contracting efforts on elective and semi-elective cardiac procedures such as:

  • Coronary artery bypass graft
  • Valve repair and replacement
  • Elective catheterization and stent placement
  • Cardiac rhythm management procedures

For these procedures, the same bundle logic applies: define the episode, price it in advance, make device and facility economics visible, and track meaningful outcomes such as readmissions and complications.

Infusion

Infusion deserves its own category because it combines high specialty-drug spend with large site-of-care variation and recurring treatment schedules.

That creates a different playbook:

  • Identify the member early in the treatment pathway.
  • Confirm clinical appropriateness of alternate sites of care.
  • Compare hospital outpatient, physician-office, ambulatory infusion center, and home-infusion economics where clinically appropriate.
  • Define drug acquisition and administration pricing clearly.
  • Make navigation and prior-authorization workflows part of the operating model, not an afterthought.
  • Track whether members actually move into the lower-cost contracted channel.

The opportunity is not simply a lower negotiated rate. It is changing the path the claim takes before the expensive site of care becomes the default.


Contract Provisions That Matter in Specialty Deals

Regardless of specialty, these provisions belong in a serious direct contract:

  • All-inclusive or clearly defined episode pricing. Avoid ambiguity around facility fees, ancillary services, and excluded charges.
  • Data sharing requirements. The provider or administrator should supply claims-level or encounter-level information sufficient to measure utilization, outcomes, and savings.
  • Out-of-area coverage coordination. Employees living or traveling outside the primary service area need a defined pathway.
  • Centers of excellence designation criteria. Define what qualifies a provider rather than relying on the label alone.
  • Steerage incentives for employees. A direct contract does nothing if employees do not use it.
  • Baseline and savings methodology. Specify what price is being compared, whether savings are gross or net of vendor fees, and how cases without historical claims are benchmarked.
  • Stop-loss coordination. High-cost specialty claims often interact with specific and aggregate stop-loss coverage, so the contract cannot be designed in isolation.

What Employers Get Wrong

The most common mistake is treating specialty direct contracting as a procurement exercise rather than a care management strategy. Signing a bundled payment contract and walking away does not produce savings. The contract is the beginning, not the end.

Employers that execute well tend to do three things consistently:

  1. They communicate clearly about preferred providers and the financial benefit of using them.
  2. They assign care-navigation support — in-house or through a vendor — to guide employees through specialty episodes.
  3. They review utilization, outcomes, and savings regularly and renegotiate based on actual performance.

The newer predictive-navigation model adds a fourth requirement: identify eligible members early enough to influence the pathway.

A negotiated rate has limited value if the member is discovered only after the referral, authorization, and treatment site are already locked in.


The Bottom Line

Primary care direct contracts reduce administrative friction and can improve access. Specialty direct contracts attack a different problem: the largest, most variable claims.

The two strategies are complementary, not interchangeable.

The next generation of specialty contracting is also becoming more operational. Employers increasingly need more than a provider agreement. They need a system that can identify addressable demand, validate the care, engage the member, route the case, and then apply the contracted economics.

That is why infusion and predictive specialty navigation are worth watching now. The contract still matters. But in high-cost specialty care, the ability to find and steer the claim may matter just as much as the negotiated rate.

Get the Weekly Direct Contract Briefing

Every Friday, the deals, the contract terms, and the market moves that matter for self-insured employers.

More in Strategy